The use of nanoparticle drug is rapidly growing as it holds several advantages over conventional treatments including high drug specificity, prolonged drug half-life, and reduced drug toxicity.
Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028 Report Highlights:
- Global Nanoparticle Drug Delivery Market Opportunity > USD 300 Billion by 2028
- Nanoparticle Drug Deliver Price & Dosage Insight By Therapeutic (Cancer, Anemia, Autoimmune Diseases, Neurological Disorders)
- Nanoparticle Therapeutics Approved Drugs Sales Analysis & Forecast Till 2028
- Global Nanoparticle Drugs Clinical Pipeline Insight By Phase, Company & Indication
- Nanoparticle Drug Delivery - Market Trend & Patent Distribution Analysis
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646380145
Nanomedicine is relatively new but rapidly growing field in which nanomaterials such as liposomes, microtubules, or other nanoparticles are introduced to targeted site for a variety of applications, such as imaging, diagnosis, and delivery of drugs to treat complex diseases such as cancer and chronic diseases. The use of nanoparticle drug is rapidly growing as it holds several advantages over conventional treatments including high drug specificity, prolonged drug half-life, and reduced drug toxicity. Till date, a cocktail of nanoparticle drug has entered the market which has shown positive impact on the management of various therapeutic indications including cancer, central nervous system (CNS) diseases, cardiovascular disease, and infection control.
The encouraging response of nanoparticle drugs has led to significant growth in this segment from last few years. Apart from this, various products are present at different phases of industry life cycle. Huge investments in research and development segment could be attributed as main reason behind growth of this market segment. The overall pipeline of nanoparticle drug is highly concentrated and consists of several potential candidates including Promitil, ThermoDox, Oncoprex, EP0057, Nanocort, NLG-207, Liposomal Annamycin, and others. These are expected to enter the market in coming years which will drive the growth of market during the forecast period.
The increasing number of companies which are investing in research and development in this field are helping to expand the market. There are also strategic alliances among leading pharmaceutical companies and technology developers which further boost the growth of market. The strategic merger and acquisition and collaboration followed by players in the market allow the companies to take technological advantage which allows them to stay ahead in competition. For instance, NewLink Genetics Corporation entered into exclusive worldwide license agreement with Ellipses Pharma Limited for the development of and rights to commercialize NLG207, a nanoparticle formulation of topoisomerase 1 inhibitor camptothecin. Apart from this, LipoMedix and ForDoz also entered into manufacturing agreement for the development of Promitil in US.
By therapeutic indication, cancer nanoparticle segments is one of the largest and most developed segments containing multiple products in market such as Doxil, Myocet, Mepact, Lipusu, Onivyde, and others. Apart from this, various nanomedicines for oncology applications are being developed by pharmaceutical companies for generating significant revenues. For instance, InteRNA Technologies recently annoaunced the US FDA clearance of IND application for phase-I clinical trial evaluating lead miRNA candidate, INT-1B3, in patients with advanced solid tumors. INT-1B3 is a lipid nanoparticle (LNP) formulated, chemically modified mimic of the endogenous tumor suppressor, miR-193a-3p, and represents a promising novel therapeutic approach that is designed to simultaneously address multiple hallmarks of cancer.
As per our report findings, it is estimated that global nanoparticle drug market will surpass US$ 300 Billion by 2028. The global market is driven by the emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support and funding, growth in need for therapies with fewer side effects, and cost-effectiveness of therapies. In addition, availability of large number of cost effective generic drugs and increasing accessibility to population also enhances the uptake of nanoparticle drugs in the market. The major key players in the market include Abbvie, Amgen, Pfizer, Tandem Nano, Horizon Therapeutics, Biogen, Bristol Myers Squibb, Nanobiotix, and others.
Our report provides an in-depth analysis of the global nanoparticle drug market and the current market trends and future estimations. The report also covers the nanoparticle drugs available in the market and their patent, price, generic availability, dosage, and sales analysis. Further, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com